35 results about "Vector vaccine" patented technology

The invention relates to a genome large fragment deleted duck adenovirus B2 strain and application thereof, the duck adenovirus B2 strain is duck adenovirus B2 DAdV-B2 / delta ORF55-ORF19, and is preserved in China Center for Type Culture Collection on September 26, 2025, and the preservation number is CCTCC NO: V202568. Compared with the duck adenovirus B2 strain BGMH, the duck adenovirus B2 strain has a deletion region between ORF20 and ORF53 genes, and the duck adenovirus B2 strain is deleted by 7422 bp. According to the invention, the duck adenovirus B2 strain with the genome deleted in large fragment is found for the first time, and the deletion region of the virus is a good site for inserting an exogenous gene, so that the duck adenovirus B2 DAdV-B2 / delta ORF55-ORF19 can be used as a good virus vector to construct a recombinant virus, and the constructed recombinant virus can be stably inherited; the method can be applied to waterfowl novel recombinant virus vector vaccine research and development, waterfowl basic scientific research, gene virus vector delivery and the like, and has wide application prospect and value.

The present invention relates to an atomized inhalable vaccine formulation and a preparation method therefor. The formulation comprises an active ingredient and auxiliary materials. The active ingredient is an antigen protein-expressing recombinant human replication-defective adenovirus at a low concentration. The auxiliary materials include a buffer, a protectant, a stabilizer, a surfactant, and an osmotic pressure regulator. The atomized inhalable vaccine formulation of the present invention can retain the good stability of a human replication-defective adenovirus vector vaccine formulation.

The application relates to the technical field of biological medicine, and particularly discloses a fish rhabdovirus recombinant adenovirus vector vaccine and a preparation method and application thereof. The recombinant adenovirus vaccine carrying the M gene of the SCRV virus is prepared by using a replication-defective recombinant adenovirus vector, and the preparation method comprises the following steps: mandarin fish rhabdovirus M gene cloning, construction of a Pshuttle-CMV-ECMV vector with a target gene SCRV-M, obtaining of a SCRV-M recombinant adenovirus plasmid, screening of the SCRV-M recombinant adenovirus, and preparation of the SCRV-M recombinant adenovirus vaccine. The SCRV-M recombinant adenovirus vaccine prepared by the application can be used for immunoprophylaxis of SCRV virus infection in the juvenile fish stage through a soaking mode, the SCRV-M recombinant adenovirus vaccine has passed an animal safety test, and has a wide application prospect in the prevention and control of fish rhabdovirus.

The invention belongs to the technical field of biological medicine, and particularly relates to a rabies virus G protein carrier, a rabies virus vaccine and a preparation method and application of the rabies virus G protein carrier and the rabies virus vaccine. The rabies virus G protein vector pscAAV-G is obtained by inserting a coding gene of rabies virus G protein into a coding region between inverted terminal repetitive sequences at two ends of a double-chain adeno-associated virus vector, so that the problem of expression delay of single-chain AAV (ssAAV) is solved, and rapid and efficient expression of the rabies virus G protein is realized; furthermore, an endogenous nucleic acid adjuvant is embedded into a non-coding region of the pscAAV-G, so that the rabies virus G protein carrier pscAAV-G-Adj is prepared, and Th1 type immune response is remarkably improved. According to a rabies virus vaccine prepared by using the rabies virus G protein carrier, the antigen expression efficiency and immunogenicity of an AAV carrier vaccine are remarkably improved, long-acting protection of single inoculation is realized, and the defects that an existing rabies vaccine is short in immune cycle and needs to be inoculated for multiple times are overcome.

The invention relates to the field of aquaculture, in particular to a preparation method and application of a recombinant live vector vaccine for infectious hematopoietic necrosis of fish. In order to solve the problem of prevention and control of the infectious hematopoietic necrosis of the fish in the aquatic product industry, a replication-defective adenovirus type 5 is selected as a target gene expression vector to construct a recombinant adenovirus vector comprising a glycoprotein gene and a nucleoprotein gene of the infectious hematopoietic necrosis virus of the fish, and a recombinant virus is obtained; the safe and effective recombinant live vector vaccine for the infectious hematopoietic necrosis of the fish is created. According to the vaccine, immunization is carried out on fishes in a soaking or bait feeding mode, the total CPM of the fishes immunized by the vaccine is 6.67%, and the total CPM of the fishes in a non-immunized control group is 94.00%. In addition, the RPS of the vaccination group fish and the RPS of the empty vector control group fish are 92.90% and 9.22% respectively. The method is at a leading level in the field of fish biological medicines at present and has remarkable creativity.

The invention relates to the field of animal health. In particular, the present invention relates to a composition comprising a modified duck enteritis virus (DEV) comprising and capable of expressing a heterologous polynucleotide encoding an antigen of a chicken pathogen. In addition, the present invention relates to a composition comprising the modified DEV as a chicken vector vaccine and uses thereof. More particularly, the present invention relates to a vaccine composition against chicken pathogens comprising a modified DEV that does not exhibit or exhibits reduced pathogenicity in chicken.

The invention provides an individualized mRNA composition, a carrier, an mRNA vaccine and application thereof, and belongs to the technical field of biological vaccines. Wherein the individualized mRNA composition comprises at least one neoantigen mRNA encoding a tumor neoantigen and at least one associated antigen mRNA encoding a tumor associated antigen. According to the present invention, the new antigen mRNA and the related antigen mRNA are combined to obtain the individualized vaccine material having the high tumor killing biological activity characteristic, such that the targeting killing ability of the tumor specific T cell is increased while the immune system activation progress is accelerated, the human body immune response can be improved, and the possible recurrence in the subsequent process can be prevented.

This invention provides a virus-like particle vaccine gE-eVLP for varicella-zoster virus, a recombinant adenovirus vector vaccine, an mRNA vaccine, and their preparation methods and applications, belonging to the field of vaccine technology. The nucleotide sequence of the virus-like particle vaccine gE-eVLP provided by this invention includes a signal peptide sequence, a truncated and / or mutated sequence of the gE domain without the original signal peptide, and an EGE motif; the recombinant adenovirus vector vaccine and mRNA vaccine contain gE-eVLP. This invention innovatively integrates EABR self-assembled particle technology into the VZV adenovirus vector vaccine and mRNA vaccine technology platform, and systematically evaluates the immunogenicity of three novel vaccines: Ad26-tPA-gE-eVLP, AdC68-tPA-gE-eVLP, and LNP-tPA-gE-eVLP, providing important experimental evidence for the development of a new generation of highly effective and safe VZV vaccines.

The present invention relates to the field of animal health. Particularly, the present invention relates to a modified Duck Enteritis Virus (DEV). More particularly, the present invention relates to a modified DEV that shows no or reduced pathogenicity in chicken. Furthermore, the present invention relates to a composition, comprising the modified DEV of the invention as vector-vaccine for chicken, and the use thereof.

The invention belongs to the technical field of biological medicines, and particularly relates to a lactic acid bacteria live vector vaccine for preventing and treating brucellosis and a preparation method of the lactic acid bacteria live vector vaccine. The lactic acid bacteria live vector vaccine is obtained by transferring expression vectors for expressing Brucella omp19 protein and BvrR protein into lactic acid bacteria, and the lactic acid bacteria are lactobacillus cavings. The lactobacillus live vector vaccine for preventing and treating brucellosis is constructed by taking brucella omp19 protein and BvrR protein as immunogens and lactic acid bacteria as an antigen transfer vector, and the safety is good. After the vaccine is used for immunizing mice, the mice can obtain a higher antibody level, the duration is long, brucella infection is effectively inhibited, meanwhile, the production process of the vaccine is simplified, and the vaccine has a good application prospect.

The present invention regards a new recombinant HVT (rHVT) construct, useful as multivalent vector vaccine for poultry. The rHVT comprises 4 heterologous genes from poultry pathogens: the VP2 gene from IBDV, the F gene from NDV, and the gD and gI genes from ILTV. The VP2 and F genes are inserted in the Us genome region of the rHVT. The gD-gI genes are inserted in the UL genome region, between the UL54 and the LORF3 genes. The new rHVT-VP2-F-gD-gI proved to be genetically stable in vitro and in vivo, and expressed all inserted genes well. Also it was an effective vaccine against severe challenge infections with NDV, IBDV, and ILTV.

This invention discloses a PRRSV NADC30 lineage vaccine, its preparation method, and its applications, belonging to the field of immunology technology. The recombinant chimpanzee adenovirus vector is obtained by introducing the encoding gene of GP35 fusion protein or M-GP5 fusion protein into an expression vector; wherein, the GP35 fusion protein is constructed by linking GP3 and GP5 proteins with a flexible linker peptide; the M-GP5 fusion protein is constructed by linking M and GP5 proteins with a flexible linker peptide. The PRRSV NADC30 lineage vaccine of this invention achieves protection against PRRSV infection by inducing antigen-specific antibodies, neutralizing antibodies, Th1-type cellular immune responses, and / or lymphocyte proliferation reactions. This invention provides a promising candidate antigen and a highly efficient vaccine platform for developing novel recombinant chimpanzee adenovirus vector vaccines against currently circulating NADC30-like strains.

The application discloses a single-chain circular DNA virus GyH1 recombinant polyepitope adenovirus vector vaccine and application thereof, and belongs to the technical field of vaccines.The antigen epitopes of GyH1 VP1, VP2 and VP3 proteins are screened through an online bioinformation analysis server, the antigen epitopes are connected by using a linker to construct a polyepitope vaccine GyMEV, and the nucleotide sequence of the GyMEV is obtained through reverse translation and codon optimization.The antigen polypeptide GyMEV nucleotide sequence is cloned into a plasmid vector pMD19-T through artificial synthesis, the GyMEV is directionally cloned into a linearized adenovirus vector by using seamless cloning technology to obtain a recombinant adenovirus plasmid rAd5-GyMEV, and the recombinant plasmid is transfected into HEK 293 cells to obtain the recombinant polyepitope adenovirus vector vaccine GyMEV.The results show that the GyMEV can more effectively stimulate the immune response of the body and has stronger protection.The vaccine also has the safety of a subunit vaccine and can adopt various immunization modes, can stimulate the immune response of the body in all directions, and thus has a wide development and application prospect.

The invention discloses an angiotensin II receptor type 1 immunogenic short peptide and application thereof. The amino acid sequence of the immunogenic short peptide is as shown in SEQ ID No.1: AFHYE. The effective component of the immunogenic vector vaccine is formed by coupling immunogenic oligopeptide and a vector. Immunogenic oligopeptides and a Qbeta carrier are coupled to obtain the vaccine effective component of the angiotensin II receptor type 1 immunogenic peptide fragment. The immunogenic carrier vaccine prepared from the active ingredients is used for antihypertensive treatment of primary hypertension, can be used as a long-acting antihypertensive drug, and is beneficial to improving the treatment compliance of patients with primary hypertension, so that the purpose of effectively controlling blood pressure is achieved.

The present application relates to a kind of recombinant adenovirus vector vaccine inhalation delivery system, the delivery system is by the modification of adenovirus vector itself and cooperate specific formulation prescription, vaccine is inhaled after inhalation administration, can reach lung by nasal cavity or oral inhalation, to generate protective immune response including mucosal immunity, while solving adenovirus pre-existing immunity, enhance the effective utilization rate of vaccine, improve the effect of vaccine.

The present invention relates to an intestinal microorganism-based composition for enhancing the efficacy of vaccinations, in particular, the persistence of antibody reactions and booster effects. The present inventors have found that specific intestinal microorganisms are significantly abundant in individuals having a long antibody half-life following vaccination with an mRNA vaccine or an adenovirus vector vaccine, or exhibiting a high immune response upon booster vaccination. Specifically, it was found that a specific microbial community including Faecalibacterium prausnitzii is associated with antibody persistence and booster response enhancement following mRNA vaccination, and Escherichia coli is associated with antibody persistence following adenovirus vector vaccination.

The present invention provides compositions and methods for immunizing a subject in need thereof again an avian pathogen. In one aspect, the invention provides a composition for immunizing an avian subject against a pathogen comprising: a) a recombinant laryngotracheitis virus vector (rLT); and b) a fusion gene of an avian virus (F) inserted into the recombinant laryngotracheitis virus vector (rLT / F); wherein the recombinant laryngotracheitis virus vector inserted with the fusion gene of the avian virus (rLT / F) is deoptimized to generate deoptimized rLT / F vaccine candidates; and wherein the deoptimized rLT / F vaccine candidates are administered to the subject in need thereof.

The application belongs to the field of biology and discloses a rabbit-derived monoclonal antibody against chicken IFN-gamma protein, which contains a heavy chain variable region and a light chain variable region; the amino acid sequence of the heavy chain variable region of the monoclonal antibody is shown as SEQ ID No. 1; and the amino acid sequence of the light chain variable region of the monoclonal antibody is shown as SEQ ID No. 2. The rabbit-derived monoclonal antibody is named Ab-56, and has the following characteristics: 1. Compared with existing monoclonal antibodies, the rabbit-derived monoclonal antibody has strong binding capacity with interferon; 2. The rabbit-derived monoclonal antibody also has strong binding capacity with duck interferon. This provides a solid foundation for evaluation of immune protection effect of some mRNA vaccines, DNA vaccines or live virus vector vaccines and research on immune response mechanism caused by virus infection, and the rabbit-derived monoclonal antibody is not only suitable for chickens, but also suitable for ducks and even other poultry for research on vaccine evaluation and cellular immune protection mechanism. In addition, the application also provides the monoclonal antibody and application.

The application belongs to the technical field of veterinary medicine, and particularly relates to an adenovirus vector recombinant pig acute diarrhea syndrome coronavirus vaccine. The application constructs a replication-defective adenovirus vector vaccine (rAd-SADS-S) expressing a full-length SADS-CoV S protein, realizes immune induction of high-efficiency humoral and cellular immunity, and provides passive protection for milk mice through maternal antibody transmission, and overcomes the defects of no available vaccine for SADS-CoV, low protection rate in existing research, and biological safety risk.

The invention belongs to the technical field of veterinary medicine, and particularly relates to an adenovirus vector recombinant porcine acute diarrhea syndrome coronavirus vaccine. According to the invention, by constructing a replication-deficient adenovirus vector vaccine (rAd-SADS-S) expressing the full length of SADS-CoV S protein, efficient body fluid and cell immunity is induced by immunity, passive protection is provided for suckling mice through maternal antibody transfer, and the defects that no SADS-CoV vaccine is available and the existing research protection rate is low and the biological safety risk is caused are overcome.

The invention relates to the field of animal health. In particular, the present invention relates to a modified duck enteritis virus (DEV). More specifically, the present invention relates to a modified DEV that does not exhibit or exhibits reduced pathogenicity in chicken. Furthermore, the present invention relates to a composition comprising the modified DEV of the invention as a chicken vector vaccine and the use thereof.

The invention belongs to the technical field of gene engineering, and particularly relates to application of an MDVgC promoter in construction of a recombinant herpes virus vector vaccine. The heterologous gene expressed by the MDVgC promoter is inserted into the herpes virus, especially turkey herpes virus, Marek's disease virus, porcine pseudorabies virus, bovine herpes virus, duck plague virus, human herpes virus (type 1-8), canine herpes virus or feline herpes virus, and the constructed recombinant herpes virus vector vaccine can efficiently express the heterologous gene and is safe and effective.

This invention claims protection for a method for constructing and applying a recombinant live vector vaccine capable of simultaneously expressing the classical swine fever virus (CSFV) E2 gene and IL18 gene. After transfecting MARC-145 cells with the chimeric plasmid pPRRSV-E2-N-IL18-Y, live virus was successfully rescued. Furthermore, the recombinant virus rPRRSV-E2-N-IL18-Y was found to have similar virological characteristics to the parental virus vHuN4-F112 and the recombinant virus rPRRSV-E2. In porcine immunization experiments using the recombinant virus rPRRSV-E2-N-IL18-Y, it was found that the recombinant virus exhibited good safety in pigs, effectively inducing an immune response after immunization, producing high levels of antibodies against both the PRRSV N protein and the CSFV E2 protein, and inducing even higher levels of cellular immunity. This makes it a promising candidate strain for a genetically engineered vaccine.

The invention relates to a multi-HBV immunogen viral vector vaccine comprising: a viral vector comprising an immunogen expression cassette, wherein the expression of a protein encoded by the expression cassette is arranged to be driven by a promoter, wherein the immunogen expression cassette encodes: a) HBV Core; b) a modified HBV polymerase (Pmut), wherein the modification is a mutation to wild-type HBV polymerase to substantially remove polymerase function; c) HBV surface antigen (HbsAg); and d) an intergenic sequence that is arranged to cause expression of at least the HBV surface antigen (HbsAg) as a separate protein from the HBV core and the modified HBV polymerase (Pmut), wherein the intergenic sequence is downstream (3′) of the sequences encoding the HBV core and the modified HBV polymerase (Pmut) and upstream (5′) of the sequence encoding the HBV surface antigen (HbsAg); and related compositions, vaccination methods and methods of treatment or prophylaxis of HBV infection.

The invention discloses a recombinant Marek's virus vector vaccine strain for expressing H9N2 subtype avian influenza virus HA protein and application of the recombinant Marek's virus vector vaccine strain, and belongs to the technical field of veterinary biological products. The amino acid sequence of the HA protein expressed by the recombinant Marek's virus vector vaccine strain is as shown in SEQ ID NO. 1. The amino acid sequence of the HA protein is obtained by modifying the 84th amino acid of the amino acid sequence shown as SEQ ID NO.2 into tryptophan from serine, eliminating the 82nd glycosylation site of the HA protein, replacing the signal peptide of the HA gene with the Ig lambda signal peptide of chicken, and adding GGGGS linker and one tetanus toxin T cell epitope to the carboxyl terminal of the HA protein. The vaccine strain is good in in-vitro proliferation characteristic, stable in genome heredity and capable of stably expressing HA protein, no side reaction or pathogenic effect exists after SPF chicken is immunized, 100% protection against H9N2 strain attack can be provided 21 days after immunization, and the problem that the immune protection blank period of other vaccines such as H9N2 inactivated vaccines is long is solved.

The present invention provides an artificially designed novel NRG-1 nucleic acid molecule, a protein variant thereof, a vector, a vaccine, a cell, a pharmaceutical composition, and a protein composition. Also provided are a method for using the product to produce a protein and a primary RNA polynucleotide, and a use in preparation of a product for preventing, alleviating or treating cardiovascular diseases and neurological diseases, a product for maintaining normal functions of heart cells or tissues, and a vaccine.

The present invention relates to the veterinary field in general and specifically to the development of vectored vaccines using the Gallid alphaherpesvirus 3 (GaHV-3) or Marek's disease serotype 2 (MDV-2) vector, which contains protective antigens against different avian pathogens such as Newcastle disease virus (NDV), infectious laryngotracheitis virus (ILTV), infectious bursal disease virus (IBDV) or Gumboro disease, avian influenza virus (AIV), and infectious bronchitis virus (IBV).

This invention relates to a reverse genetics operating system for the segmented cloning and rescue of the Bartha K61 pseudorabies virus vaccine strain genome, its construction method, and its application. The system includes: recombinant plasmids BAC-cm-PRV-EA, BAC-cm-PRV-BC, and BAC-cm-PRV-FG containing the complete genome of the Bartha K61 pseudorabies virus vaccine strain, and host cells expressing the complete genome of the Bartha K61 pseudorabies virus vaccine strain. The reverse genetics operating system for the Bartha K61 pseudorabies virus vaccine strain of this invention successfully segments the Bartha K61 genome into six segments using ExoCET cloning and assembly technology, and then assembles them into three recombinant plasmids: BAC-cm-PRV-EA, BAC-cm-PRV-BC, and BAC-cm-PRV-FG. These three recombinant plasmids, after PacI linearization, can be co-transfected into African green monkey kidney cells to rescue the Bartha K61 virus, and the infectivity of the rescued Bartha K61 virus is comparable to that of the vaccine strain. Therefore, this reverse genetics operating system can provide an excellent vector for creating live vector vaccines related to the prevention and treatment of swine diseases, and can be used to develop Bartha K61 recombinant genetic engineering vector vaccines that express relevant swine disease antigen genes.

The present invention describes a recombinant herpesvirus of turkeys (rHVT) that can be used as a vector vaccine for poultry against infection and disease from multiple poultry pathogens. Specifically the rHVT expresses an infectious bursal disease virus (IBDV) viral protein 2 (VP2) gene and a Newcastle disease virus (NDV) fusion (F) protein gene from a first and a second expression cassette inserted in the unique small (Us) region, and expresses an avian influenza vims (AIV) haemagglutinin (HA) gene from a third expression cassette inserted in the unique long (UL) region of the genome of said rHVT either between the UL40 and UL41 genes, or between the UL44 and UL45 genes. This rHVT can be used to vaccinate poultry against MDV, IBDV, NDV and AIV.

The invention relates to an aerosol inhalation vaccine preparation and a preparation method thereof. The preparation comprises effective components and auxiliary materials, the effective component is low-concentration recombinant human replication-deficient adenovirus expressing antigen protein, and the auxiliary materials comprise a buffer agent, a protective agent, a stabilizer, a surfactant and an osmotic pressure regulator. The aerosol inhalation vaccine preparation provided by the invention can maintain good stability of the human replication-deficient adenovirus vector vaccine preparation.